PerMel-AI: Identification and validation of personalized therapeutic targets and biomarkers for melanoma using artificial intelligence
Grant nr.: 2024-1.2.1-HE_PARTNERSÉG-2025-00034
Start date: 1 May 2025
End date: 30 April 2028
Grant amount: 90.592.500 HUF
The PerMel-AI project aims to revolutionize the treatment of melanoma, the most aggressive form of skin cancer, through the application of artificial intelligence and large-scale biobanking. This international consortium, comprised of leading academic and industry experts, focuses on validating novel drug targets and companion biomarkers, forming the foundation for personalized melanoma therapies. By integrating the data from the Human Melanoma Proteome Atlas with AI-driven analyses, the project enables precise patient stratification and the development of therapies tailored to the genetic and molecular profiles of individual tumors.
Melanoma is a complex and heterogeneous disease, where therapeutic responses often remain unpredictable despite advances in immunotherapy and targeted treatments. The PerMel-AI project seeks to address this challenge by identifying and validating biomarkers and therapeutic targets that enhance diagnostic precision and improve the effectiveness of treatments.
A key component of the project is the use of AI-based technologies such as Turbine Simulated Cell Platform and AI-based digital pathology, which facilitates single-cell level analysis of tumors and a detailed understanding of tumor heterogeneity. Simultaneously, the integration of clinical and molecular data aims to develop reliable predictive biomarkers and drug targets, eventually transforming them into personalized diagnostic tools and therapeutic protocols.
The project aspires to achieve significant advancements not only in research but also in clinical practice. Beyond validating new biomarkers and drug targets, the project emphasizes maximizing societal impact through the efficient dissemination of results via scientific publications, conferences, and events aimed at patients and healthcare professionals. The PerMel-AI initiative strives to set a new benchmark in oncology, improving patient outcomes and quality of life while driving innovation in personalized cancer care.
